MacroGenics | MGNX - Ebitda


MacroGenics reported $-30.2M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Amgen USD 3.86B 1.28B Mar/2026
AstraZeneca USD 5.16B 510M Jun/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 10.29B 1.86B Mar/2026
Genmab DKK 186M 291M Dec/2025
Geron USD 3.83M 25.12M Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Xencor USD -121.37M 70.32M Mar/2026